New option for the initial management of metastatic pancreatic cancer?
作者信息
Abbruzzese James L, Hess Kenneth R
机构信息
Duke Cancer Institute, Durham, NC
University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
J Clin Oncol. 2014 Aug 10;32(23):2405-7. doi: 10.1200/JCO.2013.54.4155. Epub 2014 Jun 30.
Abstract
摘要
相似文献
1
New option for the initial management of metastatic pancreatic cancer?
J Clin Oncol. 2014 Aug 10;32(23):2405-7. doi: 10.1200/JCO.2013.54.4155. Epub 2014 Jun 30.
2
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
N Engl J Med. 2014 Jan 30;370(5):479-80. doi: 10.1056/NEJMc1314761.
3
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
N Engl J Med. 2014 Jan 30;370(5):478. doi: 10.1056/NEJMc1314761.
4
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
N Engl J Med. 2014 Jan 30;370(5):478-9. doi: 10.1056/NEJMc1314761.
5
Pancreatic cancer: standing on the shoulders of mice, making an iMPACT on pancreatic cancer.
Nat Rev Clin Oncol. 2013 Dec;10(12):665. doi: 10.1038/nrclinonc.2013.209. Epub 2013 Nov 5.
6
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Clin Adv Hematol Oncol. 2018 Sep;16 Suppl 17(9):5-7.
7
[Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
Bull Cancer. 2015 May;102(5):403-4. doi: 10.1016/j.bulcan.2015.03.004. Epub 2015 Apr 9.
8
Multidisciplinary management of pancreatic cancer.
J Natl Compr Canc Netw. 2015 May;13(5 Suppl):700-2. doi: 10.6004/jnccn.2015.0208.
9
The winning formulation: the development of paclitaxel in pancreatic cancer.
Clin Cancer Res. 2013 Oct 15;19(20):5572-9. doi: 10.1158/1078-0432.CCR-13-1356. Epub 2013 Aug 5.
10
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
JOP. 2013 Jul 10;14(4):344-6. doi: 10.6092/1590-8577/1650.
引用本文的文献
1
Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients.
Cancers (Basel). 2021 Aug 17;13(16):4131. doi: 10.3390/cancers13164131.
2
Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State.
Cells. 2020 Jun 28;9(7):1572. doi: 10.3390/cells9071572.
3
Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors.
Oncotarget. 2019 Apr 23;10(30):2869-2886. doi: 10.18632/oncotarget.26880.
4
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 2016 Aug 10;34(23):2784-96. doi: 10.1200/JCO.2016.67.1412. Epub 2016 May 31.
5
Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles.
Transl Oncol. 2015 Jun;8(3):196-203. doi: 10.1016/j.tranon.2015.03.011.
6
Organoid models of human and mouse ductal pancreatic cancer.
Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.
本文引用的文献
1
Chimeric antigen receptor therapy for cancer.
Annu Rev Med. 2014;65:333-47. doi: 10.1146/annurev-med-060512-150254. Epub 2013 Nov 20.
2
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Nature. 2013 Nov 28;503(7477):548-51. doi: 10.1038/nature12796. Epub 2013 Nov 20.
3
Targeting metabolic scavenging in pancreatic cancer.
Clin Cancer Res. 2014 Jan 1;20(1):6-8. doi: 10.1158/1078-0432.CCR-13-2570. Epub 2013 Oct 28.
4
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
5
Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Clin Cancer Res. 2014 Jan 1;20(1):120-30. doi: 10.1158/1078-0432.CCR-13-0150. Epub 2013 Sep 11.
6
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.
7
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
Nature. 2013 Apr 4;496(7443):101-5. doi: 10.1038/nature12040. Epub 2013 Mar 27.
8
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.
Cell. 2012 Apr 27;149(3):656-70. doi: 10.1016/j.cell.2012.01.058.
9
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Cancer Cell. 2012 Mar 20;21(3):418-29. doi: 10.1016/j.ccr.2012.01.007.
10
Therapeutic strategies for targeting ras proteins.
Genes Cancer. 2011 Mar;2(3):359-72. doi: 10.1177/1947601911412376.
Zotero 插件